Diabetes mellitus and acute coronary syndromes

Main Article Content

V.A. Serhiyenko
A.A. Serhiyenko

Abstract

This review article summarizes the existing literature on the current state of the problem of diabetes mellitus and acute coronary syndromes. In particular, the issues are analyzed related to the etiology, epidemiology, main pathophysiological features, classification of acute coronary syndromes, acute coronary syndromes without persistent ST-segment elevation on the electrocardiogram, acute coronary syndromes with ST-segment elevation, non-athe­rosclerotic causes of acute coronary syndrome, laboratory and instrumental diagnostic tests. Issues were analyzed related to the main approaches to the treatment of acute coronary syndromes, management of patients with diabetes mellitus and acute coronary syndromes, recommendations for secondary prevention. Initial treatment with corticosteroids includes acetylsalicylic acid, bolus heparin and intravenous heparin infusion (in the absence of contraindications). Antiplatelet therapy with ticagrelor or clopidogrel is also recommended. Pain is controlled using morphine/fentanyl and oxygen in case of hypoxia. Nitroglycerin can also be used sublingually or by infusion to relieve pain. Continuous monitoring of myocardial activity for arrhythmia is required. The choice of reperfusion strategy in patients with diabetes mellitus should be based on many factors, including assessment of clinical status (hemodynamic/electrical instability, prolonged ischemia), complications of chronic coronary syndrome, ischemic load, echocardiography, assessment of left ventricular function and any other comorbidities. In addition, various methods for assessing coronary artery disease and predicting mortality due to surgery are needed to make a final decision. Advances in the sensitivity of cardiac biomarkers and the use of risk assessment tools now enable rapid diagnosis within a few hours of symptom onset. Advances in the invasive management and drug therapy have resulted in improved clinical outcomes with resultant decline in mortality associated with acute coronary syndrome.

Article Details

How to Cite
Serhiyenko, V., and A. Serhiyenko. “Diabetes Mellitus and Acute Coronary Syndromes”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 4, Sept. 2021, pp. 346-60, doi:10.22141/2224-0721.17.4.2021.237351.
Section
Literature Review

References

Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575.

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107-111. doi:10.2991/jegh.k.191028.001.

Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Recent advances in the treatment of neuropathies in type 2 diabetes mellitus patients: Focus on benfotiamine (review and own data). In: Berhardt LV, editor. Advances in Medicine and Biology (Numbered Series). Vol 166. New York: Nova Science Publishers; 2020. 1-80 pp.

Tillin T, Hughes AD, Mayet J, et al. The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited) -- a prospective population-based study. J Am Coll Cardiol. 2013 Apr 30;61(17):1777-1786. doi:10.1016/j.jacc.2012.12.046.

Arnold SV, Lipska KJ, Li Y, et al. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. Am Heart J. 2014 Oct;168(4):466-470.e1. doi:10.1016/j.ahj.2014.06.023.

O'Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012 Jul 10;60(2):106-11. doi:10.1016/j.jacc.2012.02.059.

Foussas SG. Acute coronary syndromes and diabetes mellitus. Hellenic J Cardiol. 2016 Sep-Oct;57(5):375-377. doi:10.1016/j.hjc.2016.12.012.

Planer D, Witzenbichler B, Guagliumi G, et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol. 2013 Sep 10;167(6):2572-2579. doi:10.1016/j.ijcard.2012.06.054.

Ekmekci A, Cicek G, Uluganyan M, et al. Admission hyperglycemia predicts inhospital mortality and major adverse cardiac events after primary percutaneous coronary intervention in patients without diabetes mellitus. Angiology. 2014 Feb;65(2):154-159. doi:10.1177/0003319713488930.

Lettino M, Andell P, Zeymer U, et al. Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. Eur Heart J Cardiovasc Pharmacother. 2017 Oct 1;3(4):198-213. doi:10.1093/ehjcvp/pvw049.

Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013 Jun;165(6):918-925.e2. doi:10.1016/j.ahj.2013.01.005.

Gustafsson I, Hvelplund A, Hansen KW, et al. Underuse of an invasive strategy for patients with diabetes with acute coronary syndrome: a nationwide study. Open Heart. 2015 Feb 6;2(1):e000165. doi:10.1136/openhrt-2014-000165.

Tardif JC, L'Allier PL, Fitchett DH; Diabetes Canada Clinical Practice Guidelines Expert Committee. Management of Acute Coronary Syndromes. Can J Diabetes. 2018 Apr;42(Suppl 1):S190-S195. doi:10.1016/j.jcjd.2017.10.029.

Nikitina EA. Impact of type 2 diabetes mellitus on clinical and functional features and prognosis in patients with acute coronary syndrome. Eruditio Juvenium. 2019;7(1):11-18. doi:10.23888/HMJ20197111-18. (in Russian).

Ruda MYa, Averkov OV, Panchenko EP, Iavelov IS. Diagnostika i lechenie bol'nykh c ostrym koronarnym sindromom bez pod"ema segmenta ST elektrokardiogrammy: Rekomendatsii Obshchestva spetsialistov po neotlozhnoi kardiologii [Diagnosis and treatment of patients with acute coronary syndrome without ST-segment elevation electrocardiogram: Society of Emergency Cardiology Recommendations]. Moscow; 2015. 95 p. (in Russian).

Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for acute ST-segment elevation myocardial infarction. Russ J Cardiol. 2020;25(11):4103. doi:10.15829/1560-4071-2020-4103. (in Russian).

Zègre-Hemsey JK, Asafu-Adjei J, Fernandez A, Brice J. Characteristics of Prehospital Electrocardiogram Use in North Carolina Using a Novel Linkage of Emergency Medical Services and Emergency Department Data. Prehosp Emerg Care. 2019 Nov-Dec;23(6):772-779. doi:10.1080/10903127.2019.1597230.

Alomari M, Bratton H, Musmar A, Al Momani LA, Young M. Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention. Cureus. 2019 Jan 12;11(1):e3874. doi:10.7759/cureus.3874.

Kerneis M, Nafee T, Yee MK, et al. Most Promising Therapies in Interventional Cardiology. Curr Cardiol Rep. 2019 Mar 13;21(4):26. doi:10.1007/s11886-019-1108-x.

Alekseeva MA, Asymbekova EU. Acute coronary syndrome in diabetes mellitus. Clin Physiol Circulation. 2018;15(3):162-168. doi:10.24022/1814-6910-2018-15-3-162-168. (in Russian).

Voudris KV, Kavinsky CJ. Advances in Management of Stable Coronary Artery Disease: the Role of Revascularization? Curr Treat Options Cardiovasc Med. 2019 Mar 11;21(3):15. doi:10.1007/s11936-019-0720-9.

Pop C, Matei C, Petris A. Anticoagulation in Acute Coronary Syndrome: Review of Major Therapeutic Advances. Am J Ther. 2019 Mar/Apr;26(2):e184-e197. doi:10.1097/MJT.0000000000000913.

Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome. 2020 Jul 17. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2021 Jan.

Wei CH, Litwin SE. Hyperglycemia and adverse outcomes in acute coronary syndromes: is serum glucose the provocateur or innocent bystander? Diabetes. 2014 Jul;63(7):2209-2212. doi:10.2337/db14-0571.

Severino P, D'Amato A, Pucci M, et al. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. Int J Mol Sci. 2020 Oct 30;21(21):8118. doi:10.3390/ijms21218118.

Sweis RN, Jivan A. Overview of acute coronary syndromes (ACS) (Unstable Angina; Acute MI; Myocardial Infarction). Available from: https://www.msdmanuals.com/professional/cardiovascular-disorders/coronary-artery-disease/overview-of-acute-coronary-syndromes-acs. Accessed: July 2020.

Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russ J Cardiol. 2021;26(4):4449. doi:10.15829/1560-4071-2021-4449. (in Russian).

Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi:10.1093/eurheartj/eht296.

Lee JW, Moon JS, Kang DR, et al. Clinical Impact of Atypical Chest Pain and Diabetes Mellitus in Patients with Acute Myocardial Infarction from Prospective KAMIR-NIH Registry. J Clin Med. 2020 Feb 12;9(2):505. doi:10.3390/jcm9020505.

Waterbury TM, Tarantini G, Vogel B, Mehran R, Gersh BJ, Gulati R. Non-atherosclerotic causes of acute coronary syndromes. Nat Rev Cardiol. 2020 Apr;17(4):229-241. doi:10.1038/s41569-019-0273-3.

Luciano LSC, Silva RLD, Londero Filho OM, et al. Analysis of the Appropriate Use Criteria for Coronary Angiography in Two Cardiology Services of Southern Brazil. Arq Bras Cardiol. 2019 May;112(5):526-531. doi:10.5935/abc.20190055.

Campanile A, Castellani C, Santucci A, et al. Predictors of in-hospital and long-term mortality in unselected patients admitted to a modern coronary care unit. J Cardiovasc Med (Hagerstown). 2019 May;20(5):327-334. doi:10.2459/JCM.0000000000000785.

Chen WWC, Law KK, Li SK, et al. Extended dual antiplatelet therapy for Asian patients with acute coronary syndrome: expert recommendations. Intern Med J. 2019 Mar;49 Suppl 1:5-8. doi:10.1111/imj.14153.

Aksoy A, Agirbasli M. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med. 2019 Dec 19;381(25):2482-2483. doi:10.1056/NEJMc1913971.

Stadnik SM. Cardiac troponins in clinical practice. Emergency Med. 2020;16(1):45-51. doi:10.22141/2224-0586.16.1.2020.196928. (in Ukrainian).

Gao X, Zeng R, Liao P, Zhu H, Zhang M. Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2016 Oct;76(6):460-464. doi:10.1080/00365513.2016.1199048.

Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi:10.1093/eurheartj/ehx393.

Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-1387. doi:10.1056/NEJMoa1301092.

Ahn KT, Seong SW, Choi UL, et al. Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention. Medicine (Baltimore). 2019 Mar;98(11):e14833. doi:10.1097/MD.0000000000014833.

Duarte GS, Nunes-Ferreira A, Rodrigues FB, et al. Morphine in acute coronary syndrome: systematic review and meta-analysis. BMJ Open. 2019 Mar 15;9(3):e025232. doi:10.1136/bmjopen-2018-025232.

Gilutz H, Shindel S, Shoham-Vardi I. Adherence to NSTEMI Guidelines in the Emergency Department: Regression to Reality. Crit Pathw Cardiol. 2019 Mar;18(1):40-46. doi:10.1097/HPC.0000000000000165.

Klein MD, Williams AK, Lee CR, Stouffer GA. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647-652. doi:10.1161/ATVBAHA.118.311963.

Koval SM, Yushko KO, Snihurska IO, et al. Relations of angiotensin-(1-7) with hemodynamic and cardiac structural and functional parameters in patients with hypertension and type 2 diabetes. Arterial Hypertension (Poland) 2019;23(3):183-189. doi:10.5603/AH.a2019.0012.

Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013 May;43(5):1006-1013. doi:10.1093/ejcts/ezt017.

Bonin M, Mewton N, Roubille F, et al. Effect and Safety of Morphine Use in Acute Anterior ST-Segment Elevation Myocardial Infarction. J Am Heart Assoc. 2018 Feb 10;7(4):e006833. doi:10.1161/JAHA.117.006833.

McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi:10.1056/NEJMoa1409077.

Shah R, Rashid A, Hwang I, Fan TM, Khouzam RN, Reed GL. Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. Am J Cardiol. 2017 Jun 1;119(11):1723-1728. doi:10.1016/j.amjcard.2017.03.011.

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi:10.1056/NEJMoa1615664.

Han X, Zhang Y, Yin L, et al. Statin in the treatment of patients with myocardial infarction: A meta-analysis. Medicine (Baltimore). 2018 Mar;97(12):e0167. doi:10.1097/MD.0000000000010167.

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi:10.1056/NEJMoa1801174.

Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016 Apr 7;37(14):1133-1142. doi:10.1093/eurheartj/ehv531.

Schjerning Olsen AM, Lindhardsen J, Gislason GH, et al. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ. 2015 Oct 19;351:h5096. doi:10.1136/bmj.h5096.

Sehested TSG, Carlson N, Hansen PW, et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J. 2019 Jun 21;40(24):1963-1970. doi:10.1093/eurheartj/ehz104.

James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010 Dec;31(24):3006-3016. doi:10.1093/eurheartj/ehq325.

Ruda MYa, Averkov OV, Panchenko EP, Iavelov IS. Guideline for the management of patients with non-ST-elevation acute coronary syndromes (part 2). Russ Cardiol Bull. 2018;13(1):58-62. doi:10.17116/Cardiobulletin201813159-62. (in Russian).

Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23;375(9711):283-293. doi:10.1016/S0140-6736(09)62191-7.

Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016 Jun 14;67(23):2732-2740. doi:10.1016/j.jacc.2016.03.529.

Serhiyenko VA, Serhiyenko AA. Diabetes mellitus and chronic coronary syndrome. Mìžnarodnij endokrinologìčnij žurnal. 2021;17(1):62-74. doi:10.22141/2224-0721.17.1.2021.226431. (in Ukrainian).

Abdur Rehman K, Wazni OM, Barakat AF, et al. Life-Threatening Complications of Atrial Fibrillation Ablation: 16-Year Experience in a Large Prospective Tertiary Care Cohort. JACC Clin Electrophysiol. 2019 Mar;5(3):284-291. doi:10.1016/j.jacep.2018.11.013.

Xia K, Wang LF, Yang XC, et al. Comparing the effects of depression, anxiety, and comorbidity on quality-of-life, adverse outcomes, and medical expenditure in Chinese patients with acute coronary syndrome. Chin Med J (Engl). 2019 May 5;132(9):1045-1052. doi:10.1097/CM9.0000000000000215.